Journal article
CYP2D6 polymorphisms and atypical antipsychotic weight gain
Psychiatric genetics, Vol.12(1), pp.55-58
03/2002
DOI: 10.1097/00041444-200203000-00008
PMID: 11901361
Abstract
Reports have linked atypical antipsychotics (AAPs) with weight gain. The polymorphic CYP2D6 involved in metabolism has been associated with medication morbidity. Eleven subjects receiving olanzapine were genotyped for CYP2D6 to examine the relationship between 2D6 and AAP weight gain. Using a linear regression, the dependent variable was percent change in body mass index (BMI). Genotype, dose and duration of treatment were independent. Genotype was significant (P<0.0097) for those with a *1/*3 or *4 genotype experiencing a larger percent BMI change than those with a *1/*1 genotype. This may be due to increased olanzapine concentrations leading to increased exposure, which may trigger AAP weight gain.
Details
- Title: Subtitle
- CYP2D6 polymorphisms and atypical antipsychotic weight gain
- Creators
- Vicki L Ellingrod - College of Pharmacy, University of Iowa, Iowa City, Iowa, USA. vicki-ellingrod@uiowa.eduDel MillerSusan K SchultzHeidi WehringStephan Arndt
- Resource Type
- Journal article
- Publication Details
- Psychiatric genetics, Vol.12(1), pp.55-58
- DOI
- 10.1097/00041444-200203000-00008
- PMID
- 11901361
- NLM abbreviation
- Psychiatr Genet
- ISSN
- 0955-8829
- eISSN
- 1473-5873
- Publisher
- England
- Language
- English
- Date published
- 03/2002
- Academic Unit
- Psychiatry; Biostatistics; Nursing; Injury Prevention Research Center; Internal Medicine
- Record Identifier
- 9984003421102771
Metrics
16 Record Views